

Pecuniary benefits 2022 Mundipharma Medical Company, Hamilton, Bermuda, Basel Branch												
												Date of publication: 30 th June 2023
	Full Name <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered <i>(Art. 3)</i>	Country of Principal Practice <i>(Schedule 1)</i>	Principal Practice Address <i>(Art. 3)</i>	Unique country identifier <i>OPTIONAL</i> <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b & 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c & 3.01.2.c)</i>		TOTAL <i>OPTIONAL</i>
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	
INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
HCPs	Prof. Dr. med. Jörg Leuppi	Liestal	Switzerland	Kantonsspital Baselland, Rheinstrasse 26, 4410 Liestal		N/A	N/A	CHF 450	CHF 490			CHF 940
	Prof. Dr. med. Matti Aapro	Genolier	Switzerland	Genolier Cancer Center, Clinique de Genolier, 3 route du Muids, 1272 Genolier		N/A	N/A		CHF 2250	CHF 4487		CHF 6,737
	Dr. med. Anita Gutierrez	Aarau	Switzerland	Hirslanden Klinik, Rain 34, 5000 Aarau		N/A	N/A			CHF 600		CHF 600
	Prof. Dr. med. Jan Gärtner	Basel	Switzerland	Palliativzentrum Hildegard, St. Alban-Ring 151 CH-4052 Basel		N/A	N/A			CHF 750		CHF 750
	Dr. med. Marie-Laure Amram	Genève	Switzerland	Hôpitaux Universitaires de Genève, Service d'oncologie, Rue Gabrielle-Perret-Gentil 4, 1205 Genève		N/A	N/A			CHF 750		CHF 750
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02						N/A	N/A	CHF 450	CHF 2,740	CHF 6,587		CHF 9,777
Number of Recipients in aggregate disclosure - Art. 3.02						N/A	N/A	1	3	5		9
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02						N/A	N/A	4.60%	28%	67.40%		N/A
INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
HCOs	Centre Hospitalier Universitaire Vaudois	Lausanne	Switzerland	Rue du Bugnon 21, 1011 Lausanne						CHF 2,400		CHF 2,400
	GSASA Schweizerischer Verein der Amts- und Spitalapotheker	Bern	Switzerland	3000 Bern				CHF 3,600				CHF 3,600
	Medworld AG / Kantonsspital Winterthur	Winterthur	Switzerland	Brauerstrasse 15, 8400 Winterthur				CHF 2,000				CHF 2,000
	Medworld AG / palliative ch	Biel/Bienne	Switzerland	Koehergasse 6, 3011 Bern				CHF 2,500				CHF 2,500
	Congrex Switzerland Ltd. / Swiss Society of Pneumology	Basel	Switzerland	Reinacherstrasse 131, 4053 Basel				CHF 2,200				CHF 2,200
	Forum Medizin Fortbildung (FomF)	Zürich	Switzerland	Oberneuhofstrasse 6, 6340 Baar				CHF 3,400				CHF 3,400
	Stiftung Tox Info Suisse	Zürich	Switzerland	Freiestrasse 16, 8032 Zürich			CHF 2,000					CHF 2,000
	Universitäre psychiatrische Kliniken Basel UPK	Basel	Switzerland	Wilhelm Kleinstrasse 27, 4002 Basel				CHF 2,000				CHF 2,000
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02						CHF 2,000	CHF 15,700			CHF 2,400		CHF 20,100
Number of Recipients in aggregate disclosure - Art. 3.02						1	6			1		8
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02						9.95%	78.10%			11.95%		N/A
R & D	AGGREGATE DISCLOSURE											
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											

latest update: 11 December 2013 v1